Humana Inc (HUM)vsSanofi ADR (SNY)
HUM
Humana Inc
$350.08
+0.08%
HEALTHCARE · Cap: $45.53B
SNY
Sanofi ADR
$44.38
+4.74%
HEALTHCARE · Cap: $104.85B
Smart Verdict
WallStSmart Research — data-driven comparison
Humana Inc generates 190% more annual revenue ($137.20B vs $47.35B). SNY leads profitability with a 16.0% profit margin vs 0.8%. HUM appears more attractively valued with a PEG of 2.15. HUM earns a higher WallStSmart Score of 52/100 (C-).
HUM
Buy52
out of 100
Grade: C-
SNY
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+23.7%
Fair Value
$403.67
Current Price
$350.08
$53.59 discount
Margin of Safety
+5.5%
Fair Value
$49.78
Current Price
$44.38
$5.40 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Revenue surging 23.5% year-over-year
Generating 1.1B in free cash flow
Reasonable price relative to book value
Large-cap with strong market position
Conservative balance sheet, low leverage
Strong operational efficiency at 20.0%
Generating 1.7B in free cash flow
Areas to Watch
Expensive relative to growth rate
ROE of 6.1% — below average capital efficiency
0.8% margin — thin
Operating margin of 4.7%
Expensive relative to growth rate
Earnings declined 11.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : HUM
The strongest argument for HUM centers on Altman Z-Score, Price/Book, Revenue Growth. Revenue growth of 23.5% demonstrates continued momentum.
Bull Case : SNY
The strongest argument for SNY centers on Price/Book, Market Cap, Debt/Equity. Profitability is solid with margins at 16.0% and operating margin at 20.0%.
Bear Case : HUM
The primary concerns for HUM are PEG Ratio, Return on Equity, Profit Margin. A P/E of 40.5x leaves little room for execution misses. Thin 0.8% margins leave little buffer for downturns.
Bear Case : SNY
The primary concerns for SNY are PEG Ratio, EPS Growth.
Key Dynamics to Monitor
HUM profiles as a growth stock while SNY is a mature play — different risk/reward profiles.
HUM carries more volatility with a beta of 0.77 — expect wider price swings.
HUM is growing revenue faster at 23.5% — sustainability is the question.
SNY generates stronger free cash flow (1.7B), providing more financial flexibility.
Bottom Line
HUM scores higher overall (52/100 vs 51/100) and 23.5% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Humana Inc
HEALTHCARE · HEALTHCARE PLANS · USA
Humana Inc. is a for-profit American health insurance company based in Louisville, Kentucky.
Visit Website →Sanofi ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.
Compare with Other HEALTHCARE PLANS Stocks
Want to dig deeper into these stocks?